original ) (raw )High-Affinity, Protective Antibodies to the Binding Domain of Botulinum Neurotoxin Type A
edna torres
Infection and Immunity, 2001
View PDFchevron_right
Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms
Flora Chen
Infection and Immunity, 1997
View PDFchevron_right
Antagonism of the intracellular action of botulinum neurotoxin type A with monoclonal antibodies that map to light-chain epitopes
Bernard Poulain
European Journal of Biochemistry, 1994
View PDFchevron_right
Production and characterization of a recombinant chimeric antigen consisting botulinum neurotoxin serotypes A, B and E binding subdomains
Valiollah Babaeipour
The Journal of toxicological sciences, 2010
View PDFchevron_right
Identifying the principal protective antigenic determinants of type A botulinum neurotoxin
edna torres
Vaccine, 1998
View PDFchevron_right
Molecular Characterization of Murine Humoral Immune Response to Botulinum Neurotoxin Type A Binding Domain as Assessed by Using Phage Antibody Libraries
Theresa Smith
1997
View PDFchevron_right
Immunological characterization of the subunits of type A botulinum neurotoxin and different components of its associated proteins
Bal R Singh
Toxicon, 2009
View PDFchevron_right
Recombinant proteins that trigger production of antibodies recognizing botulinum neurotoxin while not possessing sequences of this toxin
Alexey Zdanovsky
Toxicon, 2013
View PDFchevron_right
Generation of a Recombinant Full-Length Human Antibody Binding to Botulinum Neurotoxin A
David Mah
Applied Biochemistry and Biotechnology, 2010
View PDFchevron_right
Monoclonal Antibodies that Inhibit the Proteolytic Activity of Botulinum Neurotoxin Serotype/B
Theresa Smith
Toxins, 2015
View PDFchevron_right
Protective potential of recombinant non-purified botulinum neurotoxin serotypes C and D
Clovis Moreira Jr
Anaerobe, 2016
View PDFchevron_right
Bivalent Recombinant Vaccine for Botulinum Neurotoxin Types A and B Based on a Polypeptide Comprising Their Effector and Translocation Domains That Is Protective against the Predominant A and B Subtypes
Prof. Makie Taal
Infection and Immunity, 2009
View PDFchevron_right
Immunochemical characterization of type a botulinum neurotoxin in its purified and complexed forms
balbir B singh
Toxicon, 1996
View PDFchevron_right
Characterization of a highly neutralizing single monoclonal antibody to botulinum neurotoxin type A
Christine Escargueil
The FASEB Journal, 2021
View PDFchevron_right
An epitopic approach to designing and characterization of a multiple antigenic polypeptide against Botulinum neurotoxins A and E
Mohsen Basiri
View PDFchevron_right
Protein Domain Analysis of C. botulinum Type A Neurotoxin and Its Relationship with Other Botulinum Serotypes
Uma Basavanna
2010
View PDFchevron_right
Production and purification of a chimeric monoclonal antibody against botulinum neurotoxin serotype A
Michael Meagher
Protein Expression and Purification, 2004
View PDFchevron_right
Cloning, Expression, and One-Step Purification of the Minimal Essential Domain of the Light Chain of Botulinum Neurotoxin Type A
Bernhard Rupp
Protein Expression and Purification, 2000
View PDFchevron_right
The C Terminus of the Catalytic Domain of Type A Botulinum Neurotoxin May Facilitate Product Release from the Active Site
Robert Webb
Journal of Biological Chemistry, 2013
View PDFchevron_right
Comparative study of immunological and structural properties of two recombinant vaccine candidates against botulinum neurotoxin type E
Nader Sheibani
Iranian biomedical journal, 2012
View PDFchevron_right
Immunogenic and protective potentials of recombinant receptor binding domain and a C-terminal fragment of Clostridium botulinum neurotoxin type E
Mohsen Basiri
View PDFchevron_right
Characterization of immune response induced against catalytic domain of botulinum neurotoxin type E
Ram Kumar Dhaked
Scientific Reports
View PDFchevron_right
The Botulinum Neurotoxin Complex and the Role of Ancillary Proteins
Bal R Singh
Molecular Aspects of Botulinum Neurotoxin, 2014
View PDFchevron_right
Epitope Characterization and Variable Region Sequence of F1-40, a High-Affinity Monoclonal Antibody to Botulinum Neurotoxin Type A (Hall Strain)
Larry Stanker
PLoS ONE, 2009
View PDFchevron_right
Cloning, high level expression and immunogenicity of 1163-1256 residues of C-terminal heavy chain of C. botulinum neurotoxin type E
Iraj Rasooli
Biologicals, 2010
View PDFchevron_right
A Human Monoclonal Antibody that Binds Serotype A Botulinum Neurotoxin
Md Elias
Hybridoma, 2008
View PDFchevron_right
Development of Germline-Humanized Antibodies Neutralizing Botulinum Neurotoxin A and B
Thibaut Pelat
PloS one, 2016
View PDFchevron_right
Botulinum Neurotoxin A of Mucosal and Systemic Immunity to Mucosal Vaccine Targeting Improves Onset Downloaded from
Massimo Maddaloni
View PDFchevron_right
Characterization of Botulinum Neurotoxin Type A Neutralizing Monoclonal Antibodies and Influence of Their Half-Lives on Therapeutic Activity
Christelle Mazuet
PLoS ONE, 2010
View PDFchevron_right
Production and Characterisation of a Neutralising Chimeric Antibody against Botulinum Neurotoxin A
Christelle Mazuet
PLoS ONE, 2010
View PDFchevron_right